- Conditions
- Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations
- Interventions
- TAS-117
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Santa Monica, California • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced May 22, 2026, 3:53 AM EDT